*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: Cosmos Health Inc. (NASDAQ: COSM)
COSM is our brand new NASDAQ high growth alert.
The company has a chart setup positioning for a potential breakout to new highs.
Moreover, it has a recent history of very large moves in a short period of time.
In July, the company rallied from 0.50 to a high of 1.28 in weeks!
Since then, it has experienced incredible volatility and is once again approaching its highs from July.
Over the past week, COSM has been building momentum above 1.10.
This could be setting in motion a big breakout opportunity to new 52-week highs.
In addition, COSM announced multiple accomplishments recently that could be big growth catalysts.
COSM is a NASDAQ listed "diversified, vertically integrated global healthcare group".
COSM owns a "portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®."
Growth in this market is fueled by rising health awareness, demand for natural wellness solutions, and increasing consumer interest in products that support immunity, gut health, cognition, and energy.
With both aging and younger demographics proactively investing in wellness, the U.S. remains the world's largest and most influential nutraceuticals market.
The company's "long-term direction includes, among other priorities":
- "Expanding our global reach across Europe, North America, the Middle East, and Asia."
- "Scaling branded nutraceuticals and pharmaceuticals into globally recognized products."
- "Building a proprietary therapeutics pipeline with multi-billion-dollar market potential."
- "Leveraging AI and blockchain to redefine drug discovery, intellectual property monetization, and corporate treasury management."
- "Delivering sustained shareholder returns through financial innovation, operational excellence, and long-term growth."
As the company further notes in its most recent shareholder letter from Monday:
"Harnessing a $300 Million Digital Asset Facility to Power Growth & Innovation":
"In August 2025, we secured a financing facility from a U.S. institutional investor in the maximum aggregate principal amount of $300 million in the form of senior secured convertible promissory notes. Under the terms of the notes":
- "72.5% of net proceeds from the sale of each note will be directed toward building a digital treasury reserve, including Ethereum (ETH), Bitcoin (BTC), Solana (SOL) and other digital assets."
- "The balance will be allocated to working capital and to accelerating growth initiatives, both organic and through acquisitions."
"With capacity to invest over $200 million in digital assets", COSM is "creating one of the largest corporate digital treasury reserves while also retaining significant capital for its core operations".
COSM believes this strategy:
- "Provides exposure to the upside of global digital asset adoption, increasingly embraced by governments and institutions."
- "Strengthens our ability to deploy capital across our various business segments."
- "Acts both as a diversification tool and a catalyst for growth."
Through its "subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union."
"Since acquiring Cana in 2023", COSM has "advanced a multi-million-dollar expansion to modernize its wholly owned 54,000-square-foot facility in Athens, Greece, completing Phase I upgrades in 2024".
The company believes "these investments position Cana to generate more than $10 million in recurring annual gross profit at full capacity."
"What makes Cana's transformation particularly compelling is the visibility of its long-term contract pipeline consisting of the following:"
- "Pharmex: Five-year agreement for 1.5 million bottles of Ambitasol 1L."
- "Provident Pharmaceuticals: Order book of 5.02 million units (DE3-SOLE, MIOREL, CALCIFOLIN, DEXA-DOSE, etc.), plus a landmark 10-year contract for 8 million packs across four additional products (Miorelique®, BE Union F.C., and Certorun variations)."
- "Humacology: Agreement to manufacture up to 500,000 CBD units."
- "Medical Pharmaquality: Agreement for 3 million MYCOFAGYL® pessaries annually."
COSM also "distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK".
Furthermore, "the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products."
"Key achievements include":
- "Obesity & Metabolic Disorders: Advanced CCX0722 toward clinical evaluation, positioning for entry into the global weight-management market."
- "Oncology: Acquired full rights to a WIPO-filed CNS cancer patent; filed new AI-driven patents in gliomas and hematologic malignancies with Cloudpharm and the National Hellenic Research Foundation; and secured exclusive worldwide licenses for two patented anticancer therapies targeting prostate, ovarian, and colorectal cancers."
- "Autoimmune & Neurological Disorders: Expanded pipeline with Cloudscreen-derived candidates for multiple sclerosis and inflammatory conditions."
- "Allergy Treatments: Initiated preclinical programs on novel allergy therapies."
COSM has also "entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA".
With a global distribution platform, COSM is "currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK".
In addition, "In 2024", COSM "expanded further into pharmaceuticals with the acquisition of a 10-drug generics portfolio, giving Cosmos Health direct exposure to the $400 billion global generics market".
"This diversification strengthens [their] positioning across multiple healthcare segments, from premium nutraceuticals to essential medicines, and provides a stable platform for sustainable, long-term growth."
COSM has "Six Pillars of Growth":
- "Profitability and Cash Flow: Achieving and sustaining positive operating cash flow through disciplined cost management and scaling of high-margin businesses."
- "Innovation and Intellectual Property: Expanding our R&D pipeline and advancing CCX0722 and oncology candidates, supported by Cloudscreen's AI-driven discovery engine."
- "Manufacturing Scale: Leveraging dual GMP-certified hubs in Europe and the U.S. to provide global reach, flexibility, and resilience."
- "Market Development: Expanding Sky Premium Life® and other brands across Europe, the Middle East, North America, and Asia."
- "Digital Assets and Tokenization: Building one of the largest digital treasuries in healthcare while piloting blockchain-enabled initiatives to enhance efficiency and transparency."
- "Acquisitions and Partnerships: Pursuing disciplined acquisitions and alliances to broaden distribution, technology, and branded products."
COSM has announced multiple accomplishments over the past few months:
- "Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units"
- "Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven"
- "Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech"
- "Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025"
In September, alone, the company had several big accomplishments:
"Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units"
Here are some of the company's comments from this press release:
"Greg Siokas, CEO of Cosmos Health, stated: "We are excited to announce our expansion into Oman, further strengthening our presence in the rapidly growing nutraceuticals market across the GCC. This milestone showcases the exceptional quality of our products and the increasing global demand for our Sky Premium Life brand. We expect the agreement to generate significant revenue for Cosmos, supported by Scientific Pharmacy's established retail and distribution network and the rising demand for premium food supplements in Oman.""
Furthermore, last week, the company announced:
- "Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue"
In addition, the company had another big announcement:
"Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually"
"Greg Siokas, CEO of Cosmos Health, stated: "We are excited to expand our order book with long-term, high-volume commitments, further reinforcing Cana's reputation as a reliable partner in the pharmaceutical industry. This agreement reflects our partner's confidence in Cana's quality, expertise, and state-of-the-art facilities, while MYCOFAGYL represents another step in our strategy to diversify our product offerings. Women's health remains a critical therapeutic area, and this agreement not only strengthens our manufacturing pipeline but also underscores the strong growth momentum of our contract manufacturing business and our ability to secure new high-margin contracts that strengthen our cash flow."
Most recently, on Monday, the company announced:
- "Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation"
COSM could breakout to new highs.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart
Happy Trading!
UltimateStockAlerts Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.